The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review.
about
D-002 (beeswax alcohols): concurrent joint health benefits and gastroprotectionPrevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategiesNonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practiceEffect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulantsA comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an exampleSystematic review with meta-analysis: the gastrointestinal benefits of COX-2 selective inhibitors with concomitant use of low-dose aspirin.The use of H2 antagonists in treating and preventing NSAID-induced mucosal damage.EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.NSAIDs.NSAID-induced antral ulcers are associated with distinct changes in mucosal gene expression.Influence of comorbidities on therapeutic progression of diabetes treatment in Australian veterans: a cohort studyTopical delivery of aceclofenac: challenges and promises of novel drug delivery systems.Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.Quality measures for the care of patients with lateral epicondylalgia.Lansoprazole inhibits mitochondrial superoxide production and cellular lipid peroxidation induced by indomethacin in RGM1 cells.Dyspepsia and Helicobacter pylori.Age and rising rates of cyclooxygenase-2 inhibitor use. Results from a national surveyApproach to managing musculoskeletal pain: acetaminophen, cyclooxygenase-2 inhibitors, or traditional NSAIDs?Systematic review with network meta-analysis: comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity.Current evidence for osteoarthritis treatments.Fatty acid oxidation in the pathogenesis of Alzheimer's disease.Network Meta-Analysis Comparing Relatively Selective COX-2 Inhibitors Versus Coxibs for the Prevention of NSAID-Induced Gastrointestinal Injury.Proton pump inhibitors for preventing non-steroidal anti-inflammatory drug induced gastrointestinal toxicity: a systematic review.Review article: the unmet needs in delayed-release proton-pump inhibitor therapy in 2005.Gastrointestinal toxicity among patients taking selective COX-2 inhibitors or conventional NSAIDs, alone or combined with proton pump inhibitors: a case-control study.Review article: the opportunities and benefits of extended acid suppression.Nonsteroidal anti-inflammatory drugs in the treatment of low back pain.Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs.Minimizing risks of NSAIDs: cardiovascular, gastrointestinal and renal.Esomeprazole: prevention and treatment of NSAID-induced symptoms and ulcers.Conservative management of symptomatic knee osteoarthritis: a flawed strategy?Non-steroidal anti-inflammatory drugs, cyclooxygenase-2 and the bone healing process.Combination therapy versus celecoxib, a single selective COX-2 agent, to reduce gastrointestinal toxicity in arthritic patients: patient and cost-effectiveness considerations.The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage.Risk factors associated with NSAID-induced upper gastrointestinal bleeding resulting in hospital admissions: A cross-sectional, retrospective, case series analysis in valencia, spain.Acid peptic diseases: pharmacological approach to treatment.Managing the adverse effects of nonsteroidal anti-inflammatory drugs.HZT-501 (DUEXIS(®); ibuprofen 800 mg/famotidine 26.6 mg) gastrointestinal protection in the treatment of the signs and symptoms of rheumatoid arthritis and osteoarthritis.Adverse effects associated with non-opioid and opioid treatment in patients with chronic pain.
P2860
Q26824177-87F4E1B4-73E4-4E08-8AF9-7D1D909F5F56Q28200569-83C1D133-2A11-4305-A72A-C248D76F6A98Q28200864-80A8EC66-07E9-4CFA-83A4-5A8B74171CA2Q28219972-E3B203AB-78BF-4385-A986-7CDE48FC570DQ28472098-B22147FB-2E0E-46E8-A94A-BAF7C78F8A58Q30248439-EB36E44F-841A-461C-A47F-E737244F72EEQ30415171-4BE39361-8B54-4CB0-9AE4-6E65B9B7EBF7Q33260652-A62BFD49-5EDE-4902-B0CE-2CD33E46A866Q33292103-2C0092A3-9B43-4327-A36A-596E0F7AD0EEQ33448171-14CB0BD8-56BE-474D-AF13-FA1FBC467798Q33701847-CF2E9A13-A463-4020-BE85-2BB5502A1841Q33754547-8EDE9F04-07AA-4E7E-89B3-B234E981BAA7Q33862052-B358B0F7-75A3-4197-9E61-E911273AB985Q34165468-8D0C1C0A-1029-4535-85C6-5DD0524A7FB6Q35029004-1220B3BA-BF2A-43CE-827F-EABE819986DDQ35082853-300481FF-4D2A-48D9-8DB6-8C5C9A906A48Q35573791-6E423DE1-E1FD-4EA6-819A-61E2761E3830Q35688266-24CB1FEF-8EB2-4DC0-9BC0-E2835CF7B602Q35942177-FF2B8C62-91D3-425D-9D6C-E24F64A50BDDQ36001198-2D56EFA3-C6AC-4D94-90B7-80D1D53780B5Q36059344-FCFA2056-2F2C-45DB-953A-8A5495F88138Q36108432-1A068C9E-6EDC-4484-A36E-2CBB5E794F1CQ36195392-52B1E94A-7DB8-4F2A-8FB5-95306FDB1278Q36246550-6558722D-ED40-4EB6-A973-A2EC8B42400BQ36319521-8A5E82BF-A6DB-4A59-89B5-229AC905330AQ36332697-534E1565-D23E-42F1-8255-5782CBE0C940Q36478875-B80A914F-7AC3-40F1-A94B-F5909ADEF2FFQ36479456-AEA2B483-2293-47FD-9044-C8914138C3D8Q36486905-1D3E7CBD-04B1-49B3-A9BE-C06AED15933FQ36673018-1F0869ED-E1FD-4B6F-BAE8-C4CD25D798C0Q36808048-966C869E-899E-4D4F-87ED-A07F5203752FQ36869885-2F33F17B-B6F7-4B87-AA0C-64282991F78AQ36987298-CCC7DCAF-537A-4ECE-8A5C-FE7FA8014FF2Q37358250-AD2075B2-1405-4C6C-9382-DF28ADFF98B4Q37475646-9D4A098A-2712-4724-9E04-74C3A6087DA3Q37663470-DBABC378-308F-4AD1-805A-7C6F6CF0D817Q37913063-5DD52B15-3BCF-4FF8-B508-4217D7A0DCFBQ37960540-1C6FE0C7-1C2E-406A-AF70-4732A69C59ACQ37965678-7A743E39-2705-426D-8D08-3A3E7BD618DAQ37987196-5152B207-A1B2-4183-A230-8BF0C72D0112
P2860
The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review.
description
2004 nî lūn-bûn
@nan
2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
The effectiveness of five stra ...... tory drugs: systematic review.
@ast
The effectiveness of five stra ...... tory drugs: systematic review.
@en
type
label
The effectiveness of five stra ...... tory drugs: systematic review.
@ast
The effectiveness of five stra ...... tory drugs: systematic review.
@en
altLabel
The effectiveness of five stra ...... atory drugs: systematic review
@en
prefLabel
The effectiveness of five stra ...... tory drugs: systematic review.
@ast
The effectiveness of five stra ...... tory drugs: systematic review.
@en
P2860
P50
P1433
P1476
The effectiveness of five stra ...... tory drugs: systematic review.
@en
P2093
Chris Roberts
Tamara J Brown
P2860
P356
10.1136/BMJ.38232.680567.EB
P407
P577
2004-10-08T00:00:00Z